II. Indications

  1. Hirsutism: Removal of unwanted facial hair in women

III. Pharmacology

  1. Irreversible inhibitor of ornithine decarboxylase
    1. Inhibits polyamine biosynthesis
    2. Decreases polyamine mediated cell division
  2. Prior systemic use for African Trypanosomiasis
  3. Peak systemic absorption <10 ng/ml

IV. Adverse Effects: Local irritation

  1. Stinging or burning
  2. Tingling

V. Dosing (30 gram tube costs pharmacist $42)

  1. Apply thin layer to affected area bid
  2. Doses should be at least 8 hours apart
  3. Avoid washing area for 4 hours after application

VI. Efficacy

  1. Modestly effective in reducing unwanted facial hair
  2. Hair Growth recurs soon after stopping medication

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: Vaniqa (C0939525)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D000518
English vaniqa, Vaniqa, Women First Brand of Eflornithine Hydrochloride